Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: PDS' Operational Costs

Wouldn’t you think that PDS’ operational costs have got to be significant when considering the litigation with Acer, HTC/Barco. If PTSC is not funding the cash requirement of PDS what is? Are the new attorneys working on a contingency basis or ???? Perhaps we can expect to see some positive numbers today.

From the 10Q filed 10/17/2011

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

On October 6, 2011, we announced that we had settled this action with TPL see Note 11 to our condensed consolidated financial statements for terms of our settlement agreement.

With respect to PDS and TPL, we do not have any contractual commitments and do not intend to fund any cash requirements of these entities.

On October 7, 2011 PDS’ cash balance is $79,130. Management’s plans for the continued operation of PDS rely on the ability of TPL to obtain license agreements to cover the operational costs of PDS.

p.23

http://www.sec.gov/Archives/edgar/data/836564/000101968711003230/patriot_10q-083111.htm

(bold and emphasis by me)

Share
New Message
Please login to post a reply